



IPO INSIGHTS



GLOBAL HEALTH (Medanta) LIMITED

Issue Dates - Opens: 03-11-2022 | Closes: 07-11-2022

IPO Note	<ol style="list-style-type: none"> 1. Found by world renowned surgeon – Dr. Naresh Trehan 2. Largest private multi-specialty tertiary care providers operating in Northern and Eastern India 3. Only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 4. Consistent Financial Performance 5. Major Portion Offer for Sale
Rating	★★★★ (GOOD)

IPO SNAPSHOT

Issue Size	₹ 2205.57 Crores
Issue Type	Fresh Issue and Offer For Sale
Fresh Issue	₹ 500 Crores
Offer for Sale	₹ 1705.57 Crores
Face Value Per Share	₹ 2
Price Band Per Share	₹ 319 - ₹ 336
Minimum Lot Size	44 shares
Listing On	BSE,NSE
Registrar to the Issue	KFin Technologies Limited

IPO SNAPSHOT – Global Healthcare Ltd.

About the Company	<ul style="list-style-type: none"> Found by world renowned cardio-vascular and cardio-thoracic surgeon – Dr. Naresh Trehan Largest private multi-specialty tertiary care providers operating in Northern and Eastern India in terms of bed capacity & operating revenues amongst the players that operate in the North and Eastern Region in India Key Specialties: Cardiology and Cardiac Sciences, Neurosciences, Oncology, Digestive and Hepatobiliary sciences, orthopaedics, liver transplant and kidney and urology. Under brand ‘Medanta’ - network of 5 hospitals currently in operation at Gurugram, Indore, Ranchi, Lucknow and Patna One hospital in Noida is Under-Construction As of June 30, 2022, healthcare services provided in over 30 medical specialties and engage over 1300 doctors led by experienced department heads and spanning an area of 4.7 million square feet Operational Hospitals have 2467 installed beds Hospital at Gurugram ranked as the best private hospital in India for 3 consecutive years in 2020, 2021 and 2022 Only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 Featured in the list of top 250 global hospitals in 2022 by Newsweek In Fiscal 2021, Medanta took the out-patient department pharmacies in-house at their Gurugram, Lucknow, Indore, and Ranchi hospitals, and launched out-patient department pharmacy at south Delhi clinic and home care services in Gurugram and New Delhi. In Fiscal 2022, they launched the out-patient department pharmacy at their Patna hospital. 																														
Competitive Strengths	<ul style="list-style-type: none"> Tertiary & Quaternary Care Provider in India, recognized for clinical expertise particularly in dealing with complicated cases Focus on clinical research and academics Doctor-led hospitals driven by skilled and experienced doctors in healthcare space Large-scale hospitals with sophisticated infrastructure, medical equipment and technology Track record of operational and financial performance Focus on under-served areas with dense population, presence in top or capital cities of large states Growth opportunities in existing facilities and diversification into new services including digital health Experienced Senior Management & Institutional Shareholder Support 																														
Financials (₹ in Crores)	<table border="1"> <thead> <tr> <th>Particulars</th> <th>FY 2020</th> <th>FY 2021</th> <th>FY 2022</th> <th>Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue from Operations</td> <td>1500.42</td> <td>1446.74</td> <td>2166.59</td> <td>49.76%</td> </tr> <tr> <td>EBITDA</td> <td>230.45</td> <td>222.85</td> <td>489.76</td> <td>120%</td> </tr> <tr> <td>EBITDA Margin</td> <td>15.4%</td> <td>15.4%</td> <td>22.6%</td> <td></td> </tr> <tr> <td>Profit After Tax</td> <td>36.33</td> <td>28.81</td> <td>196.20</td> <td>581%</td> </tr> <tr> <td>Profit After Tax Margin</td> <td>2.42%</td> <td>1.99%</td> <td>9.06%</td> <td></td> </tr> </tbody> </table> <p>Debt to Networth = 0.52</p>	Particulars	FY 2020	FY 2021	FY 2022	Y-o-Y	Revenue from Operations	1500.42	1446.74	2166.59	49.76%	EBITDA	230.45	222.85	489.76	120%	EBITDA Margin	15.4%	15.4%	22.6%		Profit After Tax	36.33	28.81	196.20	581%	Profit After Tax Margin	2.42%	1.99%	9.06%	
Particulars	FY 2020	FY 2021	FY 2022	Y-o-Y																											
Revenue from Operations	1500.42	1446.74	2166.59	49.76%																											
EBITDA	230.45	222.85	489.76	120%																											
EBITDA Margin	15.4%	15.4%	22.6%																												
Profit After Tax	36.33	28.81	196.20	581%																											
Profit After Tax Margin	2.42%	1.99%	9.06%																												
Valuation	<ul style="list-style-type: none"> Attributing Q1FY23 Annualized Earnings, asking P/E = 38.37 																														
Peers	<table border="1"> <thead> <tr> <th>Name Of the Company</th> <th>TTM P/E</th> </tr> </thead> <tbody> <tr> <td>Apollo Hospital Enterprises</td> <td>58.53</td> </tr> <tr> <td>Fortis Healthcare Ltd</td> <td>37.31</td> </tr> <tr> <td>Max Healthcare Institute</td> <td>68.55</td> </tr> <tr> <td>Narayana Hrudayalaya</td> <td>43.33</td> </tr> </tbody> </table>	Name Of the Company	TTM P/E	Apollo Hospital Enterprises	58.53	Fortis Healthcare Ltd	37.31	Max Healthcare Institute	68.55	Narayana Hrudayalaya	43.33																				
Name Of the Company	TTM P/E																														
Apollo Hospital Enterprises	58.53																														
Fortis Healthcare Ltd	37.31																														
Max Healthcare Institute	68.55																														
Narayana Hrudayalaya	43.33																														
Promoters	<ul style="list-style-type: none"> Dr. Naresh Trehan 																														
Objects of the issue	<ul style="list-style-type: none"> Fresh Issue for Repayment or Prepayment of borrowings for subsidiaries GHPPL & MHPL Offer for Sale 																														

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

